Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia.

Acta Biomater

Department of Materials Science, Graduate School of Pure and Applied Sciences, Master's School of Medical Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8573, Japan; Master's School of Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan; Center for Research in Isotopes and Environmental Dynamics (CRiED), University of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8573, Japan. Electronic address:

Published: June 2020

Although Levodopa (l-DOPA), a dopamine precursor, exhibits a high risk of dyskinesia, it remains the primary treatment in Parkinson's disease (PD), a progressive neurodegenerative disorder. In this study, we designed poly(l-DOPA)-based self-assembled nanodrug (Nano) from amphiphilic block copolymer possessing poly(l-DOPA(OAc)), which is a precursor of l-DOPA as a hydrophobic segment, for treatment in a PD model mouse. Under physiological enzyme treatment, the poly(l-DOPA(OAc)) in the block copolymer was hydrolyzed to liberate l-DOPA gradually. Using the MPTP-induced PD mouse model, we observed that mice treated with Nano demonstrated a significant improvement of PD symptoms compared to the l-DOPA treatment. Interestingly, the Nano treatment did not cause the dyskinesia symptoms, which was clearly observed in the l-DOPA-treated mice. Furthermore, Nano exhibited remarkably lower toxicity in vitro compared to l-DOPA, in addition with no noticeable Nano toxicity observed in the treated mice. These results suggested that self-assembled Nano is a promising therapeutic in the treatment of PD. STATEMENT OF SIGNIFICANCE: In this study, we proposed a therapeutic approach for the effective treatment of Parkinson's disease (PD) using newly designed poly(l-DOPA)-based self-assembled nanodrug (Nano) prepared from amphiphilic block copolymers possessing poly(l-DOPA(OAc)), which is a precursor of l-DOPA as a hydrophobic segment, for treatment in a PD model mouse. Under physiological enzyme treatments, Nano was hydrolyzed to liberate l-DOPA gradually, improving the pharmacokinetic value of l-DOPA. The mice treated with Nano significantly improved PD symptoms compared to the l-DOPA treatment in a neurotoxin-induced PD mouse model. Interestingly, Nano treatment did not cause dyskinesia symptoms, which was observed in the l-DOPA-treated mice. The obtained results in this study suggested that self-assembled Nano is a promising therapeutic in the treatment of PD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.actbio.2020.03.021DOI Listing

Publication Analysis

Top Keywords

treatment
12
treatment parkinson's
12
parkinson's disease
12
compared l-dopa
12
nano
11
l-dopa
9
designed polyl-dopa-based
8
polyl-dopa-based self-assembled
8
self-assembled nanodrug
8
nanodrug nano
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!